{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T22:26:04Z","timestamp":1794435964060,"version":"4.9.1"},"reference-count":63,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Nucleic Acids"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.omtn.2026.102936","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:04:25Z","timestamp":1776384265000},"page":"102936","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["A computational model-powered platform to inform the development of GalNAc-conjugated siRNA therapeutics"],"prefix":"10.1016","volume":"37","author":[{"given":"Xiaoqing","family":"Fan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kangna","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruijie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0009-4313","authenticated-orcid":false,"given":"Xiaoyu","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtn.2026.102936_bib1","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nature02873","article-title":"Mechanisms of gene silencing by double-stranded RNA","volume":"431","author":"Meister","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2026.102936_bib2","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jconrel.2014.07.056","article-title":"Current issues of RNAi therapeutics delivery and development","volume":"195","author":"Haussecker","year":"2014","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.omtn.2026.102936_bib3","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1016\/j.ymthe.2020.06.015","article-title":"Delivery of Oligonucleotides to the Liver with GalNAc: From Research to Registered Therapeutic Drug","volume":"28","author":"Debacker","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2026.102936_bib4","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/jcph.2337","article-title":"Pharmacokinetics and Pharmacodynamics of GalNAc-Conjugated siRNAs","volume":"64","author":"An","year":"2024","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.omtn.2026.102936_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2024.106981","article-title":"A journey into siRNA therapeutics development: A focus on Pharmacokinetics and Pharmacodynamics","volume":"205","author":"Choi","year":"2025","journal-title":"Eur. J. Pharmaceut. Sci."},{"key":"10.1016\/j.omtn.2026.102936_bib6","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1007\/s11095-022-03333-8","article-title":"Pharmacokinetic and Pharmacodynamic Modeling of siRNA Therapeutics - a Minireview","volume":"39","author":"Jeon","year":"2022","journal-title":"Pharm. Res."},{"key":"10.1016\/j.omtn.2026.102936_bib7","doi-asserted-by":"crossref","first-page":"6407","DOI":"10.1021\/acs.jmedchem.9b01839","article-title":"Emerging siRNA Design Principles and Consequences for Biotransformation and Disposition in Drug Development","volume":"63","author":"Humphreys","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.omtn.2026.102936_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2024.115503","article-title":"Applications of pharmacometrics in drug development","volume":"217","author":"Xiong","year":"2025","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.omtn.2026.102936_bib9","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1124\/jpet.121.000805","article-title":"Minimal Physiologically Based Pharmacokinetic-Pharmacodynamic (mPBPK-PD) Model of N-Acetylgalactosamine-Conjugated Small Interfering RNA Disposition and Gene Silencing in Preclinical Species and Humans","volume":"379","author":"Ayyar","year":"2021","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.omtn.2026.102936_bib10","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.xphs.2023.10.026","article-title":"Mechanistic Pharmacokinetics and Pharmacodynamics of GalNAc-siRNA: Translational Model Involving Competitive Receptor-Mediated Disposition and RISC-Dependent Gene Silencing Applied to Givosiran","volume":"113","author":"Ayyar","year":"2024","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.omtn.2026.102936_bib11","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1007\/s40262-025-01513-4","article-title":"Prediction of Interspecies Translation for Targeting Delivery Coefficients of GalNAc-siRNA Silencing Apolipoprotein C-III Using a Mechanistic Minimal Physiologically Based Pharmacokinetic\/Pharmacodynamic Model","volume":"64","author":"Tian","year":"2025","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.omtn.2026.102936_bib12","article-title":"Analysis of the pharmacokinetics and efficacy of RBD1016 - A GalNAc-siRNA targeting Hepatitis B Virus X gene using semi-mechanistic PK\/PD model","volume":"10","author":"Li","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.omtn.2026.102936_bib13","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1002\/psp4.70023","article-title":"Less Is More: Design Considerations for Interactive Pharmacometrics Tools-A Case Study Using the Model Visualization Platform (MVP) App","volume":"14","author":"Choy","year":"2025","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"10.1016\/j.omtn.2026.102936_bib14","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1124\/jpet.122.001229","article-title":"Plasma and Liver Pharmacokinetics of the N-Acetylgalactosamine Short Interfering RNA JNJ-73763989 in Recombinant Adeno-Associated-Hepatitis B Virus-Infected Mice","volume":"383","author":"Sandra","year":"2022","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.omtn.2026.102936_bib15","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/nbt.2612","article-title":"Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape","volume":"31","author":"Gilleron","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omtn.2026.102936_bib16","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.jconrel.2023.04.012","article-title":"Advanced translational PBPK model for transferrin receptor-mediated drug delivery to the brain","volume":"357","author":"Sato","year":"2023","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.omtn.2026.102936_bib17","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2208391","article-title":"Zilebesiran, an RNA Interference Therapeutic Agent for Hypertension","volume":"389","author":"Desai","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtn.2026.102936_bib18","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.jconrel.2020.02.032","article-title":"Small interfering RNA from the lab discovery to patients' recovery","volume":"321","author":"Caillaud","year":"2020","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.omtn.2026.102936_bib19","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1124\/dmd.121.000428","article-title":"The Nonclinical Disposition and Pharmacokinetic\/Pharmacodynamic Properties of N-Acetylgalactosamine-Conjugated Small Interfering RNA Are Highly Predictable and Build Confidence in Translation to Human","volume":"50","author":"McDougall","year":"2022","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.omtn.2026.102936_bib20","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1111\/bph.70063","article-title":"Advancing antihypertensive drug development","volume":"182","author":"Pu","year":"2025","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.omtn.2026.102936_bib21","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/hr.2013.155","article-title":"Targeting of hepatic angiotensinogen using chemically modified siRNAs results in significant and sustained blood pressure lowering in a rat model of hypertension","volume":"37","author":"Olearczyk","year":"2014","journal-title":"Hypertens. Res."},{"key":"10.1016\/j.omtn.2026.102936_bib22","doi-asserted-by":"crossref","DOI":"10.3390\/ijms262110717","article-title":"Zilebesiran as an Innovative siRNA-Based Therapeutic Approach for Hypertension: Emerging Perspectives in Cardiovascular Medicine","volume":"26","author":"Morosan","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omtn.2026.102936_bib23","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1111\/hepr.12599","article-title":"Variable asialoglycoprotein receptor 1 expression in liver disease: Implications for therapeutic intervention","volume":"46","author":"Witzigmann","year":"2016","journal-title":"Hepatol. Res."},{"key":"10.1016\/j.omtn.2026.102936_bib24","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/psp4.12957","article-title":"Pharmacokinetic-pharmacodynamic model of urinary \u03b4-aminolevulinic acid reduction after givosiran treatment in patients with acute hepatic porphyria","volume":"12","author":"Lee","year":"2023","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"10.1016\/j.omtn.2026.102936_bib25","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1002\/cpt.3160","article-title":"Predicting Clinical Pharmacokinetics\/Pharmacodynamics and Impact of Organ Impairment on siRNA-Based Therapeutics Using a Mechanistic Physiologically-Based Pharmacokinetic-Pharmacodynamic Model","volume":"115","author":"Lumen","year":"2024","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.omtn.2026.102936_bib26","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1124\/dmd.119.087098","article-title":"In Vitro Drug-Drug Interaction Evaluation of GalNAc Conjugated siRNAs Against CYP450 Enzymes and Transporters","volume":"47","author":"Ramsden","year":"2019","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.omtn.2026.102936_bib27","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41392-024-02112-8","article-title":"Landscape of small nucleic acid therapeutics: moving from the bench to the clinic as next-generation medicines","volume":"10","author":"Liu","year":"2025","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.omtn.2026.102936_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2024.102437","article-title":"Development, opportunities, and challenges of siRNA nucleic acid drugs","volume":"36","author":"Xiao","year":"2025","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2026.102936_bib29","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3390\/ph19020244","article-title":"FDA TIDES (Peptides and Oligonucleotides) Harvest","volume":"19","author":"AlShaer","year":"2025","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.omtn.2026.102936_bib30","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/cpt.1802","article-title":"Pharmacokinetics and Pharmacodynamics of the Small Interfering Ribonucleic Acid, Givosiran, in Patients With Acute Hepatic Porphyria","volume":"108","author":"Agarwal","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.omtn.2026.102936_bib31","article-title":"Center for Drug Evaluation and Research","year":"2025","journal-title":"Multi-Discipline Review"},{"key":"10.1016\/j.omtn.2026.102936_bib32","article-title":"Center for Drug Evaluation and Research","year":"2025","journal-title":"Integrated Review"},{"key":"10.1016\/j.omtn.2026.102936_bib33","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.2215\/CJN.14730920","article-title":"Phase 1\/2 Study of Lumasiran for Treatment of Primary Hyperoxaluria Type 1: A Placebo-Controlled Randomized Clinical Trial","volume":"16","author":"Frishberg","year":"2021","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.omtn.2026.102936_bib34","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.1080","article-title":"The N-Acetylgalactosamine-conjugated small interfering RNA inclisiran can be coadministered safely with atorvastatin in cynomolgus monkeys resulting in additive low-density lipoprotein cholesterol reductions","volume":"11","author":"Lehoux","year":"2023","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.omtn.2026.102936_bib35","article-title":"Center for Drug Evaluation and Research","year":"2025","journal-title":"Non-Clinical Review"},{"key":"10.1016\/j.omtn.2026.102936_bib36","article-title":"Center for Drug Evaluation and Research","year":"2025","journal-title":"Clinical Pharmacology Review"},{"key":"10.1016\/j.omtn.2026.102936_bib37","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jacl.2023.04.010","article-title":"The clinical effects of inclisiran, a first-in-class LDL-C lowering siRNA therapy, on the LDL-C levels in Chinese patients with hypercholesterolemia","volume":"17","author":"Luo","year":"2023","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.omtn.2026.102936_bib38","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1615758","article-title":"Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol","volume":"376","author":"Ray","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtn.2026.102936_bib39","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/cpt.1974","article-title":"Single-Dose Pharmacokinetics and Pharmacodynamics of Transthyretin Targeting N-acetylgalactosamine-Small Interfering Ribonucleic Acid Conjugate, Vutrisiran, in Healthy Subjects","volume":"109","author":"Habtemariam","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.omtn.2026.102936_bib40","article-title":"Center for Drug Evaluation and Research","year":"2025","journal-title":"Integrated Review"},{"key":"10.1016\/j.omtn.2026.102936_bib41","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.kint.2021.08.015","article-title":"Safety, pharmacodynamics, and exposure-response modeling results from a first-in-human phase 1 study of nedosiran (PHYOX1) in primary hyperoxaluria","volume":"101","author":"Hoppe","year":"2022","journal-title":"Kidney Int."},{"key":"10.1016\/j.omtn.2026.102936_bib42","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/nm.3847","article-title":"An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia","volume":"21","author":"Sehgal","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtn.2026.102936_bib43","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1616569","article-title":"Targeting of Antithrombin in Hemophilia A or B with RNAi Therapy","volume":"377","author":"Pasi","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtn.2026.102936_bib44","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1111\/jth.15270","article-title":"Targeting of antithrombin in hemophilia A or B with investigational siRNA therapeutic fitusiran-Results of the phase 1 inhibitor cohort","volume":"19","author":"Pasi","year":"2021","journal-title":"J. Thromb. Haemostasis"},{"key":"10.1016\/j.omtn.2026.102936_bib45","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1186\/s12933-025-02929-9","article-title":"Safety, pharmacokinetics and pharmacodynamics of Plozasiran in Chinese healthy volunteers","volume":"24","author":"Wang","year":"2025","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.omtn.2026.102936_bib46","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1056\/NEJMoa2409368","article-title":"Plozasiran for Managing Persistent Chylomicronemia and Pancreatitis Risk","volume":"392","author":"Watts","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtn.2026.102936_bib47","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200325","article-title":"RNA Interference Therapy Targeting Apolipoprotein C-III in Hypertriglyceridemia","volume":"2","author":"Gaudet","year":"2023","journal-title":"NEJM Evid."},{"key":"10.1016\/j.omtn.2026.102936_bib48","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1001\/jamacardio.2024.0959","article-title":"Plozasiran (ARO-APOC3) for Severe Hypertriglyceridemia: The SHASTA-2 Randomized Clinical Trial","volume":"9","author":"Gaudet","year":"2024","journal-title":"JAMA Cardiol."},{"key":"10.1016\/j.omtn.2026.102936_bib49","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1002\/psp4.12422","article-title":"NONMEM Tutorial Part II: Estimation Methods and Advanced Examples","volume":"8","author":"Bauer","year":"2019","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"10.1016\/j.omtn.2026.102936_bib50","article-title":"R: A language and environment for statistical computing","year":"2021","journal-title":"R Foundation for Statistical Computing"},{"key":"10.1016\/j.omtn.2026.102936_bib51","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s10928-011-9232-2","article-title":"Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human","volume":"39","author":"Shah","year":"2012","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.omtn.2026.102936_bib52","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1177\/074823379701300401","article-title":"Physiological parameter values for physiologically based pharmacokinetic models","volume":"13","author":"Brown","year":"1997","journal-title":"Toxicol. Ind. Health"},{"key":"10.1016\/j.omtn.2026.102936_bib53","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1023\/A:1018943613122","article-title":"Physiological parameters in laboratory animals and humans","volume":"10","author":"Davies","year":"1993","journal-title":"Pharm. Res."},{"key":"10.1016\/j.omtn.2026.102936_bib54","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1002\/jps.22811","article-title":"Interspecies scaling in pharmacokinetics: a novel whole-body physiologically based modeling framework to discover drug biodistribution mechanisms in vivo","volume":"101","author":"Hall","year":"2012","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.omtn.2026.102936_bib55","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s10928-009-9142-8","article-title":"Selection between Michaelis-Menten and target-mediated drug disposition pharmacokinetic models","volume":"37","author":"Yan","year":"2010","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.omtn.2026.102936_bib56","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1208\/s12248-016-9975-1","article-title":"Population Pharmacokinetics of an Extended-Release Formulation of Exenatide Following Single- and Multiple-Dose Administration","volume":"19","author":"Cirincione","year":"2017","journal-title":"AAPS J."},{"key":"10.1016\/j.omtn.2026.102936_bib57","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s10928-010-9183-z","article-title":"Interpretation of transit compartments pharmacodynamic models as lifespan based indirect response models","volume":"38","author":"Krzyzanski","year":"2011","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.omtn.2026.102936_bib58","doi-asserted-by":"crossref","first-page":"16","DOI":"10.2133\/dmpk.24.16","article-title":"Scaling pharmacodynamics from in vitro and preclinical animal studies to humans","volume":"24","author":"Mager","year":"2009","journal-title":"Drug Metabol. Pharmacokinet."},{"key":"10.1016\/j.omtn.2026.102936_bib59","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2021.1964935","article-title":"Allometric scaling of therapeutic monoclonal antibodies in preclinical and clinical settings","volume":"13","author":"Germovsek","year":"2021","journal-title":"mAbs"},{"key":"10.1016\/j.omtn.2026.102936_bib60","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1208\/s12248-012-9344-7","article-title":"A physiologically based pharmacokinetic model of mitoxantrone in mice and scale-up to humans: a semi-mechanistic model incorporating DNA and protein binding","volume":"14","author":"An","year":"2012","journal-title":"AAPS J."},{"key":"10.1016\/j.omtn.2026.102936_bib61","doi-asserted-by":"crossref","first-page":"27256","DOI":"10.1021\/acsomega.3c02570","article-title":"Application of Allometric Scaling to Nanochelator Pharmacokinetics","volume":"8","author":"Jones","year":"2023","journal-title":"ACS Omega"},{"key":"10.1016\/j.omtn.2026.102936_bib62","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1124\/dmd.107.015248","article-title":"Interspecies comparisons of pharmacokinetics and pharmacodynamics of recombinant human erythropoietin","volume":"35","author":"Woo","year":"2007","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.omtn.2026.102936_bib63","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1002\/bdd.2266","article-title":"Across-species meta-analysis of dexamethasone pharmacokinetics utilizing allometric and scaling modeling approaches","volume":"42","author":"Song","year":"2021","journal-title":"Biopharm. Drug Dispos."}],"container-title":["Molecular Therapy Nucleic Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253126001071?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253126001071?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T21:35:07Z","timestamp":1794432907000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2162253126001071"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":63,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S2162253126001071"],"URL":"https:\/\/doi.org\/10.1016\/j.omtn.2026.102936","relation":{},"ISSN":["2162-2531"],"issn-type":[{"value":"2162-2531","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A computational model-powered platform to inform the development of GalNAc-conjugated siRNA therapeutics","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Nucleic Acids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtn.2026.102936","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"102936"}}